While not a primary mechanism of action, the metabolic improvements and reduced late-night eating often translate to better rest
Physical changes commonly reported include: Reduced meal portion sizes without feeling deprived Prolonged sensation of fullness after eating Changes in food preferences, often favoring lighter, less rich foods Gradual reduction in abdominal circumference as visceral fat decreases Patients should monitor for signs of inadequate nutrition, including fatigue, hair thinning, or muscle weakness, which may indicate insufficient protein or caloric intake
Semaglutide offers a promising approach to managing type 2 diabetes and obesity, with significant benefits in glycemic control and weight loss
The "Beyond-Use Date" (BUD) is assigned to ensure safety and potency within a shorter, validated timeframe
Pharmacokinetics : The pharmacokinetics of sitagliptin has been extensively characterized in healthy subjects and patients with type 2 diabetes
[DOI] [PubMed] [Google Scholar] 83.Merida E, Delgado E, Molina LM, Villanueva-Penacarrillo ML, Valverde I